The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients: a 12-week prospective study

Liu, Jiahong; Wang, Pingping; Sun, Leilei; Guan, Xiaoni; Xiu, Meihong; Zhang, Xiang Yang

doi:10.1038/s41398-021-01585-3

Cited by 5 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An interesting and pragmatic approach was taken by Liu ( 39 ), where the study focused on evaluating the relationship between BDNF levels and the BDNF genotype and weight gain in individuals with schizophrenia treated with Risperidone. While a non-significant increase in BDNF levels correlated with weight gain in Val/Val homozygous patients, these findings raise the importance of examining genetic factors underlying therapeutic response.…”

Section: Discussionmentioning

confidence: 99%

BDNF gene Val66Met polymorphisms as a predictor for clinical presentation in schizophrenia – recent findings

Farcas,

Hindmarch,

Iftene

2023

Front. Psychiatry

View full text Add to dashboard Cite

Schizophrenia is a highly heritable, severe psychiatric disorder that involves dysfunctions in thinking, emotions, and behavior, with a profound impact on a person’s ability to function normally in their daily life. Research efforts continue to focus on elucidating possible genetic underlying mechanisms of the disorder. Although the genetic loci identified to date to be significantly associated with schizophrenia risk do not represent disease-causing factors, each one of them could be seen as a possible incremental contributor. Considering the importance of finding new and more efficient pharmacological approaches to target the complex symptomatology of this disorder, in this scoping review, we are focusing on the most recent findings in studies aiming to elucidate the contribution of one of the genetic factors involved – the BDNF gene Val66Met polymorphisms. Here we performed a systematic search in Pubmed, Embase, and Web of Science databases with the search terms: (BDNF gene polymorphism) AND (schizophrenia) for articles published in the last 5 years. To be selected for this review, articles had to report on studies where genotyping for the BDNF Val66Met polymorphism was performed in participants diagnosed with schizophrenia (or schizophrenia spectrum disorders or first-episode psychosis). The search provided 35 results from Pubmed, 134 results from Embase, and 118 results from the Web of Science database. Twenty-two articles were selected to be included in this review, all reporting on studies where an implication of the BDNF Val66Met polymorphisms in the disorder’s pathophysiology was sought to be elucidated. These studies looked at BDNF gene Val66Met polymorphism variants, their interactions with other genes of interest, and different facets of the illness. The Met/Met genotype was found to be associated with higher PANSS positive scores. Furthermore, Met/Met homozygous individuals appear to present with worse cognitive function and lower levels of serum BDNF. In the Val/Val genotype carriers, increased BDNF levels were found to correlate with weight gain under Risperidone treatment. However, due to heterogeneous results, the diversity in study populations and studies’ small sample sizes, generalizations cannot be made. Our findings emphasize the need for further research dedicated to clarifying the role of gene polymorphisms in antipsychotic treatment to enhance specificity and efficacy in the treatment of schizophrenia.

show abstract

Section: Discussionmentioning

confidence: 99%

BDNF gene Val66Met polymorphisms as a predictor for clinical presentation in schizophrenia – recent findings

Farcas,

Hindmarch,

Iftene

2023

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…A growing number of studies have shown that brain-derived neurotrophic factor (BDNF) is associated with weight gain in patients with schizophrenia during antipsychotic treatment [17]. Liu et al [21] found that in patients with Val/Val genotype, the increase of serum BDNF level was negatively correlated with risperidone-induced weight gain (r = -0.44, p = 0.008), indicating that the BDNF signaling pathway may be related to risperidone-induced weight gain. In addition, the negative association between weight gain and increased BDNF levels in ANFE (antipsychotic-naive and first-episode (ANFE) schizophrenics during risperidone treatment depended on the BDNF Val66Met polymorphism.…”

Section: Therapeutic Responsementioning

confidence: 99%

Research Progress of Brain-Derived Neurotrophic Factor Val66Met Gene Polymorphism in Schizophrenia

2023

IJFM

View full text Add to dashboard Cite

Schizophrenia is now considered to be a severe mental disorder caused by complex geneenvironment interactions. Brain-derived neurotrophic factor (BDNF) is involved in the development, differentiation, and plasticity of neurons. The Val66Met polymorphism has been associated with impaired neurocognitive function in healthy adults and has been identified as a risk site for a range of neuropsychiatric disorders, including schizophrenia. In this paper, the relationship between BDNFVal66Met polymorphism and schizophrenia is reviewed.

show abstract

“…BDNF is encoded by the BDNF gene, which is located on chromosome 11 at the boundary of 11p13 and 11p14 in the human [ 32 ]. More than one hundred polymorphisms in the BDNF gene have been identified and previous evidence has pointed to some specific SNPs and positive associations with the cognitive impairments in SZ [ 33 , 34 ]. For example, evidence supports that hippocampus-dependent learning and declarative memory is influenced by the BDNF Val66Met (rs6265) variant [ 35 ].…”

Section: Introductionmentioning

confidence: 99%

Neuronavigated Repetitive Transcranial Stimulation Improves Neurocognitive Functioning in Veterans with Schizophrenia: A Possible Role of BDNF Polymorphism

liu

Wang

et al. 2023

Self Cite

View full text Add to dashboard Cite

Previous literatures have reported that high-frequency (HF) neuronavigated repetitive transcranial magnetic stimulation (rTMS) may improve neurocognitive functioning in patients with schizophrenia. Nonetheless, the heterogeneity of the research findings with regards to the effectiveness of HF-rTMS on the neurocognitive functioning in patients with schizophrenia greatly hinders its clinical application. The current study was designed to determine the predictive role of BDNF variants for neurocognitive improvements after rTMS administration in veterans with schizophrenia. 109 hospitalized veterans with schizophrenia were randomly allocated to active 10Hz rTMS (n=63) or sham stimulation (n=46) over left DLPFC for 4 consecutive weeks. Neurocognitive functions were assessed by using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at baseline and at the end of week 4. BDNF polymorphism was genotyped by the technicians. Compared with sham stimulation sessions, the immediate memory performance was significantly increased in active sessions after neuronavigated rTMS administration. In addition, patients with the CC homozygotes demonstrated greater improvement of immediate memory after rTMS treatment, while T allele carriers showed no significant improvement in immediate memory domain relative to baseline performance of immediate memory. Our findings suggest that add-on neuronavigated 10Hz rTMS is beneficial on immediate memory only in patients with CC homozygotes, but not in T allele carriers. This pilot study provides further evidence for BDNF as a promise biomarker in predicting the clinical response to rTMS stimulation.

show abstract

The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients: a 12-week prospective study

Cited by 5 publications

References 47 publications

BDNF gene Val66Met polymorphisms as a predictor for clinical presentation in schizophrenia – recent findings

BDNF gene Val66Met polymorphisms as a predictor for clinical presentation in schizophrenia – recent findings

Research Progress of Brain-Derived Neurotrophic Factor Val66Met Gene Polymorphism in Schizophrenia

Neuronavigated Repetitive Transcranial Stimulation Improves Neurocognitive Functioning in Veterans with Schizophrenia: A Possible Role of BDNF Polymorphism

Contact Info

Product

Resources

About